RT Journal Article
T1 Successful Adaptation of Bee Venom Immunotherapy in a Patient Monosensitized to Api m 10.
A1 Ruiz-Leon, B
A1 Navas, A
A1 Serrano, P
A1 Espinazo, M
A1 Labrador-Horrillo, M
A1 Monsalve, R I
A1 Jurado, A
A1 Moreno-Aguilar, C
K1 Api m 10
K1 Bee venom allergy
K1 Effectiveness of venom immunotherapy
K1 Molecular diagnosis
AB Bee venom immunotherapy (BVIT), although highly effective, does not protect 10%-15% of patients allergic to bee stings [1]. Even though the production of allergenic extracts is standardized, the real content of major components is not completely known, given the total content of allergenic proteins and the enzymatic activity of phospholipase A2 (Api m 1) and hyaluronidase (Api m 2). To date, 12 allergens have been described as components of Apis mellifera venom (AMV). Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10 are considered major allergens, and their specific IgE (sIgE) can be determined using commercially available techniques [1].
PB Esmon Publicidad
SN 1018-9068
YR 2020
FD 2020-02-25
LK http://hdl.handle.net/10668/15163
UL http://hdl.handle.net/10668/15163
LA en
NO Ruiz-León B, Navas A, Serrano P, Espinazo M, Labrador-Horrillo M, Monsalve RI, et al. Successful Adaptation of Bee Venom Immunotherapy in a Patient Monosensitized to Api m 10. J Investig Allergol Clin Immunol. 2020;30(4):296-298
DS RISalud
RD Apr 11, 2025